303043-22-3

Upstream product

• 303043-21-2 (3S,4R,5R)-3-[(4S)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy]-4-[4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl]-5-(4-methoxy-naphthalen-2-ylmethoxy)-piperidine-1-carboxylic acid tert-butyl ester 
• 33295-48-6 1-methoxy-3-(hydroxymethyl)naphthalene 
• 303043-20-1 3-Chloromethyl-1-methoxy-naphthalene 
• 303043-19-8 (3S,4R,5R)-3-((S)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-5-hydroxy-4-{4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 303043-16-5 (3R,4R,5S)-4-(4-Benzyloxy-phenyl)-5-((S)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-1-((R)-1-phenyl-ethyl)-piperidin-3-ol 
• 303043-15-4 (3S)-4-(4-benzyloxy-phenyl)-3-[(4S)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy]-1-[(R)-1-phenyl-ethyl]-1,2,3,6-tetrahydro-pyridine 
• 303043-18-7 (3S,4R,5R)-3-((S)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-5-hydroxy-4-(4-hydroxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 257928-40-8 (1R,6R)-6-(4-benzyloxy-phenyl)-3-[(R)-1-phenyl-ethyl]-7-oxa-3-aza-bicyclo [4.1.0] heptane 
• 257928-45-3 (3S)-4-(4-benzyloxy-phenyl)-1-[(1R)-phenyl-ethyl]-1,2,3,6-tetrahydro-pyridin-3-ol 
• 257928-43-1 (R)-4-(4-benzyloxy-phenyl)-1-(1-phenyl-ethyl)-1,2,3,6-tetrahydro-pyridine 
• 303043-17-6 (3R,4R,5S)-5-((S)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-4-(4-hydroxy-phenyl)-piperidin-3-ol 

Downstream Products

• 303043-23-4 (3S,4R,5R)-3-((R)-2,3-Dihydroxy-propoxy)-4-{4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl}-5-(4-methoxy-naphthalen-2-ylmethoxy)-piperidine-1-carboxylic acid tert-butyl ester 
• 303043-27-8 (3S,4R,5R)-3-[(2R)-2-hydroxy-3-methoxy-propoxy]-4-[4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl]-5-(4-methoxy-naphthalen-2-ylmethoxy)-piperidine-1-carboxylic acid tert-butyl ester 
• 303043-26-7 (3R,4R,5S)-4-[4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl]-3-(4-methoxy-naphthalen-2-ylmethoxy)-5-[(2R)-oxiranylmethoxy]-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Naphthalenylmethoxypiperidines as renin inhibitors

The present invention relates to compound of formula (I) wherein R1, R2and R3are as defined in the description and claims and pharmaceutically acceptable salts thereof. The compounds are useful for treating diseases associated with restenosis, glaucoma, cardiac infarct, high blood pressure and end organ damage, e.g. cardiac insufficiency and kidney insufficiency.

Piperidine renin inhibitors: from leads to drug candidates

Non-peptidomimetic renin inhibitors of the piperidine type represent a novel structural class of compounds potentially free of the drawbacks seen with peptidomimetic compounds so far. Synthetic optimization in two structural series focusing on improvement